Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A Multicentre, Randomised, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Study of PQ912 in Subjects With Early Alzheimer's Disease

NCT02389413 is registered in ClinicalTrials.gov with Vivoryon Therapeutics N.V. as lead sponsor.

NCT NCT02389413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02389413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A Multicentre, Randomised, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Study of PQ912 in Subjects With Early Alzheimer's Disease
Lead sponsor
Vivoryon Therapeutics N.V.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2015
Completion date
April 30, 2017
Enrollment
120 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease